## Will Stephens Vice President, Global Access & Partnerships

Jamssen Global Services, LLC One Johnson & Johnson Plaza Herr Brunswick, New Jersey 08933 732 524 2404 tel 732 713-1016 tel

Wstephe1@its.jnj.com

## 15 December 2011

Robert Weismann and Peter Maybarduk Public Citizen 1600 20th Street NW Washington, D.C. 20009 (202) 588-1000

RE: Your letter of November 7th, 2011

Dear Mr. Weismann and Mr. Maybarduk,

Thank you for your letter concerning the intention of Johnson & Johnson to announce its decision to formally enter negotiations with the Medicines Patent Pool to license the company's patents and related data to the Pool.

We believe that voluntary licensing is an ideal mechanism by which to expand access and reduce prices to HIV drugs. To that end, during 2011 we have completed five new license agreements with generic manufacturers for our newest HIV medicine *rilpivirine*. The geographic scope of our access efforts now spans 112 low- and middle-income countries. In addition we have expanded a number of our existing voluntary licensing agreements as well as our agreement with Gilead for the development of a once-daily fixed dose combination of EDURANT® (rilpivirine) and Gilead's Truvada® (*emtricitabine 200 mg/tenofovir 300 mg*). We will continue to build on and enhance our generic licensing agreements.

As a company policy, we do not disclose or discuss the details of our licensing agreements. For your information, I've attached a recent update that we shared on our access efforts and agreements.

We support the MPP Foundation in their initiative to expand voluntary licensing and are arranging for a meeting with them during which we will share the outcome of our evaluation process. After we have met with them, we will certainly make ourselves available to meet with your team to provide any further clarification and answer your questions.

With best regards,

Will Stephens

VP Global Access and Partnerships Program, Janssen global Services Inc

Sent on behalf of William C. Weldon